Novo Nordisk Executive: Oral GLP-1 Drugs to Capture Over a Third of Market by 2030
ReutersJanuary 15, 20261 min4,687 views
9 connections·14 entities in this video→Oral GLP-1 Market Growth
- 💡 A Novo Nordisk executive stated that oral weight-loss drugs are projected to capture a third or more of the overall GLP-1 market by 2030.
- 🎯 This projection is a larger percentage than the company had initially anticipated.
- 📈 Novo Nordisk's updated view is attributed to a better understanding of behavior in an increasingly consumer-driven obesity market.
Expanding Treatment Access
- 🚀 Novo Nordisk launched a daily oral version of Wegovy in the US, priced at $149 per month.
- 👥 The company believes this new oral version can expand treatment to underrepresented groups, including men and younger patients.
Market Projections and Analyst Views
- 📊 Analysts are debating the long-term role of oral GLP-1s, with some estimating pills will make up a mid-teen percentage share of global obesity drug sales by 2030.
- 💰 Estimates suggest the overall weight loss drugs market could reach $150 billion by 2030.
Knowledge graph14 entities · 9 connections
How they connect
An interactive map of every person, idea, and reference from this conversation. Hover to trace connections, click to explore.
Hover · drag to explore
14 entities
Chapters1 moments
Key Moments
Transcript5 segments
Full Transcript
Topics9 themes
What’s Discussed
GLP-1 marketOral weight-loss drugsNovo NordiskWegovyObesity marketConsumer-driven marketGLP-1 useWeight loss drugs marketMarket share projections
Smart Objects14 · 9 links
People· 4
Company· 1
Products· 2
Concepts· 7